This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): oral second-generation fumarate derivative, BG-12, BG12, dimethyl fumarate, BG00012, FAG-201, Panaclar
Description: BG-12 is an oral fumarate derivative with an immunomodulatory mechanism of action.Fumapharm AG developed this second-generation fumarate (fumaric acid) derivative for the oral treatment of psoriasis. It seems that this product has been developed to reduce the adverse effects associated with a first-generation product containing fumaric acid esters, Fumaderm.
The mechanism of action of dimethyl fumarate (DMF) is: (i) DMF interferes with intracellular thiols resulting in increased levels of reduced glutathione after prolonged exposure, through an unknown mechanism; (ii) increased glutathione levels inhibit redox-sensitive kinases, resulting in (iii) an inhibition of the phosphorylation and ubiquitination of I kappa B, leading to (iv) an inhibition of NF kappa B translocation. This pathway leads to the modulation of the NF kappa B-dependent cascades of inflammatory cytokine production and adhesion molecule expression.
Deal Structure: Revenue splits are BioMedTracker Estimates.
Biogen licensed this compound from Fumapharm in October 2003. Biogen will market the drug outside of Germany.
In May 2006, Biogen Idec announced that they signed a definitive agreement for the acquisition of Fumapharm. Upon completion, Biogen Idec will acquire all of the issued and outstanding shares of the capital stock of Fumapharm and will take over manufacture and sale of Fumaderm for the treatment of psoriasis in Germany through Fumapharm's existing network. Financial terms of the transaction were not disclosed. The transaction closed in June.
In connection with Biogen's acquisition of Fumapharm, the company agreed to make an additional payment of $15 million upon the achievement of regulatory approval for BG-12 in MS in the US and EU. Biogen also agreed to make additional payments when the cumulative net sales of Fumapharm products reached $500 million, $1 billion and at each $1 billion increment thereafter up to $20 billion....See full deal structure in Biomedtracker
Partners: Royalty Pharma AG UCB SA
Additional information available to subscribers only: